OKYO Pharma to Present at the Bio International Convention

Core Insights - OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain and inflammatory eye diseases, with its lead candidate being urcosimod [1][4] Group 1: Presentation Information - Dr. Gary S. Jacob, CEO of OKYO Pharma, will present at the Bio International Convention 2025 in Boston, covering the clinical development of urcosimod for neuropathic corneal pain [2] - The convention will take place from June 16 to June 19, 2025, at the Boston Convention & Exhibition Center [2] Group 2: Neuropathic Corneal Pain (NCP) - NCP is characterized by severe pain and sensitivity in the eyes, face, or head, often resulting from nerve damage and inflammation [2] - Current treatments for NCP are limited and primarily off-label, indicating a significant unmet medical need [2] Group 3: Urcosimod Development - Urcosimod, previously known as OK-101, is a lipid-conjugated chemerin peptide agonist targeting the ChemR23 receptor, involved in the inflammatory response [3] - The drug has demonstrated anti-inflammatory and pain-reducing effects in preclinical models and is designed to enhance its residence time in the ocular environment [3] - Urcosimod has shown statistical significance in a Phase 2 trial for dry eye disease and is currently being evaluated in a Phase 2 trial for neuropathic corneal pain [3] Group 4: Company Overview - OKYO Pharma is listed on the NASDAQ Capital Market and is dedicated to discovering and developing novel molecules for treating ocular diseases [4] - The company is actively pursuing clinical trials for urcosimod in both dry eye disease and neuropathic corneal pain [4]